肝硬化患者中急性肾损伤的代谢组学研究

摘要/Abstract

摘要： 急性肾损伤(AKI)是指由多种病因、危险因素引起的肾功能快速下降的临床综合征。肝硬化患者发生AKI的风险很高,其早期识别和治疗至关重要。代谢组学是组学领域的最新学科,具有代谢产物种类少、预测发生的生物过程准确、样本容易获得的优势,有望成为 AKI 早期诊断的新标志,鉴定 AKI 中可能存在的异常的代谢途径,探索药物治疗的新靶点以及提供个体化精准医疗。

关键词: 急性肾损伤, 肝肾综合征, 肾脏替代治疗, 慢加急性肝功能衰竭, 代谢组学

宦红娣. 肝硬化患者中急性肾损伤的代谢组学研究[J]. 肝脏, 2022, 27(1): 15-16.

[1] Angeli P, Gines P, Wong F,et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites. J Hepatol,2015,62:968-974.
[2] Huelin P, Piano S, Solà E, et al. Validation of a Staging System for Acute Kidney Injury in Patients With Cirrhosis and Association With Acute on Chronic Liver Failure. Clin Gastroenterol Hepatol,2017;15:438-445.
[3] Arroyo V, Angeli P, Moreau R, et al. The Systemic Inflammation Hypothesis: Towards a New Paradigm of Acute Decompensation and Multiorgan Failure in Cirrhosis. J Hepatol, 2021,74:670-685.
[4] Piano S, Schmidt HH, Ariza X, et al. Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome. Clin Gastroenterol Hepatol,2018,16:1792-1800.e3.
[5] Cullaro G, Park M, Lai JC. "Normal" Creatinine Levels Predict Persistent Kidney Injury and Waitlist Mortality in Outpatients With Cirrhosis. Hepatology,2018,68:1953-1960.
[6] Angeli P, Gines P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut,2015,64:531-537.
[7] Cárdenas A, Ginès P, Uriz J, et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: Incidence, clinical course, predictive factors, and short-term prognosis. Hepatology,2001,34:671-676.
[8] Fasolato S, Angeli P, Dallagnese L, et al. Renal failure and bacterial infections in patients with cirrhosis: Epidemiology and clinical features. Hepatology,2007,45:223-229.
[9] Puthumana J, Ariza X, Belcher JM, et al. Urine Interleukin 18 and Lipocalin 2 Are Biomarkers of Acute Tubular Necrosis in Patients With Cirrhosis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol,2017,15:1003-1013 e1003.
[10] Weiss RH, Kim K. Metabolomics in the study of kidney diseases. Nat Rev Nephrol,2012,8: 22-33.
[11] Zhang A, Sun H, Qiu S, et al. Metabolomics insights into pathophysiological mechanisms of nephrology. Int Urol Nephrol,2013, 46: 1025-1030.
[12] Zaccherini G, Aguilar F, Caraceni P, et al. Assessing the role of amino acids in systemic inflammation and organ failure in patients with ACLF. J Hepatol,2021, 74:1117-1131.
[13] Silva RE, Baldim JL, Chagas-Paula DA, et al. Predictive metabolomic signatures of end-stage renal disease: A multivariate analysis of population-based data. Biochimie, 2018,152:14-30.
[14] Tankiewicz A, Pawlak D, Topczewska-Bruns J,et al. Kidney and liver kynurenine pathway enzymes in chronic renal failure. Adv Exp Med Biol,2003,527:409-414.
[15] Mor A, Kalaska B, Pawlak D. Kynurenine Pathway in Chronic Kidney Disease: What’s Old, What’s New, and What’s Next? Int J Tryptophan Res,2020,13:1178.
[16] Bajaj J, Garcia-Tsao G, Reddy R, et al. Admission Urinary and Serum Metabolites Predict Renal Outcomes in Hospitalized Patients with Cirrhosis.Hepatology,2021,74:2699-2713.
[17] Poyan Mehr A, Tran MT, Ralto KM, et al. De novo NAD(+) biosynthetic impairment in acute kidney injury in humans. Nat Med,2018,24:1351-1359.
[18] Moreau R, Clària J, Aguilar F, et al. Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. J Hepatol,2020,72:688-701.
[19] Claria J, Moreau R, Fenaille F, et al. Orchestration of Tryptophan-Kynurenine Pathway, Acute Decompensation, and Acute-on-Chronic Liver Failure in Cirrhosis. Hepatology,2019,69:1686-1701.
[20] Wong F, Pappas SC, Curry MP, et al. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. N Engl J Med,2021,384:818-828.

肝硬化患者中急性肾损伤的代谢组学研究

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	冯丽娟, 贾继东. 关于肝硬化并发症诊治的共识与争议[J]. 肝脏, 2022, 27(1): 4-7.
[2]	张云, 尹伟, 郭洪雷, 李成忠. 新型生物学标志物在肝硬化AKI早期诊断和鉴别诊断中的研究进展[J]. 肝脏, 2021, 26(9): 953-955.
[3]	张警予, 赵红, 谢雯. 氨基酸在慢加急性肝衰竭病理生理机制中的作用[J]. 肝脏, 2021, 26(9): 958-960.
[4]	尹伟, 李成忠. 基于NGAL的模型在肝硬化急性肾损伤早期诊断和鉴别诊断中的意义[J]. 肝脏, 2021, 26(3): 247-251.
[5]	郝莎莎, 姚佳, 原丽莉. 肝硬化并发肝肾综合征患者预后影响因素分析[J]. 肝脏, 2021, 26(2): 151-154.
[6]	尹伟, 李成忠. 肝硬化急性肾损伤发病风险和治疗应答影响因素的前瞻性研究[J]. 肝脏, 2020, 25(8): 791-796.
[7]	高淑娟, 耿西林. 非选择性β受体阻滞剂对肝硬化合并食管胃底静脉曲张患者循环及肝肾综合征发生率的影响[J]. 肝脏, 2020, 25(8): 806-809.
[8]	董欣欣, 王海清, 王兴纯. 特利加压素对1型肝肾综合征的治疗疗效:一项系统评价及meta分析[J]. 肝脏, 2020, 25(3): 254-259.
[9]	胡掌朝, 白雪, 程帅师, 安俊丽. 奥曲肽辅助特利加压素在肝硬化失代偿期并发肝肾综合征治疗中的疗效[J]. 肝脏, 2020, 25(12): 1294-1296.
[10]	张志侨, 叶一农, 何纲, 王鹏, 李静, 吴兴柳. 乙型肝炎相关慢加急性肝衰竭患者急性肾损伤的影响因素和高危人群分析[J]. 肝脏, 2019, 24(9): 997-1001.
[11]	刘晓超, 何创业. 特利加压素治疗失代偿期肝硬化合并肝肾综合征患者的量效关系[J]. 肝脏, 2019, 24(9): 1034-1037.
[12]	徐强, 马燕, 郭峰, 王晓波, 王晓忠. 肝硬化相关急性肾损伤30天内死亡的相关因素分析[J]. 肝脏, 2019, 24(8): 857-860.
[13]	范红顺, 熊志娇, 马超, 邱少霞, 沈莉华. 小剂量激素辅助双重血浆分子吸附治疗早期慢加急性肝功能衰竭的疗效及抗SLA水平观察[J]. 肝脏, 2019, 24(7): 770-773.
[14]	李永芳, 李娟, 吴慧慧, 蔡伟, 刘芸野. 胸腺肽α1对乙型肝炎相关慢加急性肝衰竭疗效分析[J]. 肝脏, 2019, 24(6): 677-679.
[15]	周凡, 王冉. 慢加急性乙型肝炎肝衰竭患者血清OPN和IFI 16水平变化及临床意义[J]. 肝脏, 2019, 24(5): 534-537.